welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
INTRODUCTION : Management and outcomes f...
Risk of Cancer and Secondary Proctectomy After Colectomy and Ileorectal Anastomosis in Familial Adenomatous Polyposi...PURPOSE : The aim of our retrospective s...
BACKGROUND & AIMS : Familialadenomat...
Evaluation of Management of Desmoid Tumours Associated with Familial Adenomatous Polyposis in Dutch PatientsBACKGROUND : The optimal treatment of de...
Long Term Treatment with Sulindac in Familial Adenomatous Polyposis: Is there an Actual Efficiacy in Prevention of ...BACKGROUND AND OBJECTIVES : Ileorectal a...